Lakefront Biotherapeutics (GLPGF) Net Margin Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Margin Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | 388.00 |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | -15,026.00 |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | -374.00 |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | -44.00 |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | 6,620.00 |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | -13,815.00 |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 9,934.00 |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | -2,059.00 |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | -1.86 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -35,721.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35,721.00 |
| Mar 31, 2026 | 18,399.00 |
| Dec 31, 2025 | 3.58 Mn |
| Sep 30, 2025 | -71,659.00 |
| Jun 30, 2025 | 25,205.00 |
| Mar 31, 2025 | -19,484.00 |
| Dec 31, 2024 | 19.74 Mn |
| Sep 30, 2024 | -1,114.00 |
| Jun 30, 2024 | -16,568.00 |
| Mar 31, 2024 | 13,597.00 |
| Dec 31, 2023 | 3.90 Mn |
| Sep 30, 2023 | -244.00 |
| Jun 30, 2023 | 11,649.00 |
| Mar 31, 2023 | 8,846.00 |
| Dec 31, 2022 | -12,240.00 |
| Sep 30, 2022 | -3,217.00 |
| Jun 30, 2022 | 6,662.00 |
| Mar 31, 2022 | 13,747.00 |
| Dec 31, 2021 | 5,027.00 |
| Sep 30, 2021 | -6,402.00 |